Compare TBBK & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | SYRE |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 4.0B |
| IPO Year | 2005 | 2015 |
| Metric | TBBK | SYRE |
|---|---|---|
| Price | $59.56 | $64.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $69.00 | ★ $77.78 |
| AVG Volume (30 Days) | 420.5K | ★ 898.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $42.86 | $12.04 |
| 52 Week High | $81.65 | $75.00 |
| Indicator | TBBK | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 67.89 | 80.96 |
| Support Level | $50.85 | $15.23 |
| Resistance Level | $71.63 | N/A |
| Average True Range (ATR) | 1.67 | 4.11 |
| MACD | 0.90 | 1.44 |
| Stochastic Oscillator | 93.49 | 66.69 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.